ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages.
ImCare Biotech is accepted into the CARE (Connecting Awardees with Regulatory Experts) program, which is being piloted by the NCI SBIR Development Center to encourage communications between promising small businesses and the FDA.
ImCare Biotech wins the MacDougall Pitch Competition at the BIO International Convention in Philadelphia, PA
COMPANY EVENTS PRODUCTS
